These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 19435660)

  • 1. Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: alleviating hERG interactions through structure based design.
    Patel SD; Habeski WM; Cheng AC; de la Cruz E; Loh C; Kablaoui NM
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3339-43. PubMed ID: 19435660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.
    Karczewski J; Wang J; Kane SA; Kiss L; Koblan KS; Culberson JC; Spencer RH
    Biochem Pharmacol; 2009 May; 77(10):1602-11. PubMed ID: 19426697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
    Wang L; Wible BA; Wan X; Ficker E
    J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward a consensus model of the HERG potassium channel.
    Stary A; Wacker SJ; Boukharta L; Zachariae U; Karimi-Nejad Y; Aqvist J; Vriend G; de Groot BL
    ChemMedChem; 2010 Mar; 5(3):455-67. PubMed ID: 20104563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of novel quinazoline-4-piperidinesulfamide derivatives as inhibitors of NPP1.
    Forcellini E; Boutin S; Lefebvre CA; Shayhidin EE; Boulanger MC; Rhéaume G; Barbeau X; Lagüe P; Mathieu P; Paquin JF
    Eur J Med Chem; 2018 Mar; 147():130-149. PubMed ID: 29427906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels.
    Perrin MJ; Kuchel PW; Campbell TJ; Vandenberg JI
    Mol Pharmacol; 2008 Nov; 74(5):1443-52. PubMed ID: 18701618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refining insights into high-affinity drug binding to the human ether-à-go-go-related gene potassium channel.
    Hancox JC; James AF
    Mol Pharmacol; 2008 Jun; 73(6):1592-5. PubMed ID: 18381562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
    Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
    Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY; Yang SJ
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists.
    Deng Q; Lim YH; Anand R; Yu Y; Kim JH; Zhou W; Zheng J; Tempest P; Levorse D; Zhang X; Greene S; Mullins D; Culberson C; Sherborne B; Parker EM; Stamford A; Ali A
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2958-62. PubMed ID: 26048804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of (-)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone--a potent NR2B-selective N-methyl D-aspartate (NMDA) antagonist for the treatment of pain.
    Kawai M; Ando K; Matsumoto Y; Sakurada I; Hirota M; Nakamura H; Ohta A; Sudo M; Hattori K; Takashima T; Hizue M; Watanabe S; Fujita I; Mizutani M; Kawamura M
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5558-62. PubMed ID: 17766106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574).
    Gerlach AC; Stoehr SJ; Castle NA
    Mol Pharmacol; 2010 Jan; 77(1):58-68. PubMed ID: 19805508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel class of sodium/calcium exchanger inhibitors: design, synthesis, and structure-activity relationships of 4-phenyl-3-(piperidin-4-yl)-3,4-dihydro-2(1H)-quinazolinone derivatives.
    Hasegawa H; Muraoka M; Matsui K; Kojima A
    Bioorg Med Chem Lett; 2006 Feb; 16(3):727-30. PubMed ID: 16249082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
    Zachariae U; Giordanetto F; Leach AG
    J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular determinants of high-affinity drug binding to HERG channels.
    Mitcheson JS; Perry MD
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):667-74. PubMed ID: 14579516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
    Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
    J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentamidine-induced long QT syndrome and block of hERG trafficking.
    Kuryshev YA; Ficker E; Wang L; Hawryluk P; Dennis AT; Wible BA; Brown AM; Kang J; Chen XL; Sawamura K; Reynolds W; Rampe D
    J Pharmacol Exp Ther; 2005 Jan; 312(1):316-23. PubMed ID: 15340016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
    Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
    Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring Left-Hand-Side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors.
    Geng B; Comita-Prevoir J; Eyermann CJ; Reck F; Fisher S
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5432-5. PubMed ID: 21782427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.
    Berglund S; Egner BJ; Gradén H; Gradén J; Morgan DG; Inghardt T; Giordanetto F
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4274-9. PubMed ID: 19500982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.